ConductScience.org, home

Paper36947730

The Past, Present, and Future of Treatment Intensification for Metastatic Hormone-Sensitive Prostate Cancer.

McManus HD and 1 other. J Clin Oncol, 2023. Cited by 8 papers, by iCite.

Cite this record

ConductScience Library. The Past, Present, and Future of Treatment Intensification for Metastatic Hormone-Sensitive Prostate Cancer. Papers, record 36947730. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/36947730

Download JSON
Sources
11 sources
Release
papers-2026-11-12-0.1.0

Paper

PubMed's record of the paper, with iCite's citation figures. No abstract is shown.

Title
The Past, Present, and Future of Treatment Intensification for Metastatic Hormone-Sensitive Prostate Cancer.
PubMed
Journal
J Clin Oncol
PubMed
Year
2023
PubMed
Publication types
Editorial, Comment
PubMed
Citations, by iCite
8
iCite
Relative citation ratio, by iCite
0.49
iCite
Revised in PubMed
2024-07-11
PubMed

Authors2

The authors in the order PubMed's record lists them, with the ORCID iDs it states.

OrderAuthorForenameKindORCID iD
1McManus HDHannah Dhttps://orcid.org/0000-0003-1455-2976
2Armstrong AJAndrew Jhttps://orcid.org/0000-0001-7012-1754

Source PubMed

Download CSV of authors

Topics6

NLM's MeSH indexing of the paper, its major topics first.

MeSH termMajor
Prostatic NeoplasmsMajor topic
Male
Humans
Docetaxel
Hormones
Androgen Antagonists

Comments and corrections1

PubMed's comments and corrections, NLM's own indexing: retractions first, then expressions of concern, errata and updates, and comments last.

KindPMIDTitleIn Papers
Comment on36795843Darolutamide Plus Androgen-Deprivation Therapy and Docetaxel in Metastatic Hormone-Sensitive Prostate Cancer by Disease Volume and Risk Subgroups in the Phase III ARASENS Trial.https://conductscience.org/library/papers/36795843

Source PubMed

Download CSV of comments and corrections

References14

The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.

OrderPMIDTitleJournalYearIn PapersSource
135420921Improved Survival With Enzalutamide in Patients With Metastatic Hormone-Sensitive Prostate Cancer.J Clin Oncol2022https://conductscience.org/library/papers/35420921PubMed
235405085
Abiraterone plus prednisone added to androgen deprivation therapy and docetaxel in de novo metastatic castration-sensitive prostate cancer (PEACE-1): a multicentre, open-label, randomised, phase 3 study with a 2 × 2 factorial design.
Lancet2022https://conductscience.org/library/papers/35405085PubMed
335864053Treatment Intensification Patterns and Utilization in Patients with Metastatic Castration-Sensitive Prostate Cancer.Clin Genitourin Cancer2022https://conductscience.org/library/papers/35864053PubMed
434030924Overall Survival of Men with Metachronous Metastatic Hormone-sensitive Prostate Cancer Treated with Enzalutamide and Androgen Deprivation Therapy.Eur Urol2021https://conductscience.org/library/papers/34030924PubMed
529529169Adding abiraterone or docetaxel to long-term hormone therapy for prostate cancer: directly randomised data from the STAMPEDE multi-arm, multi-stage platform protocol.Ann Oncol2018https://conductscience.org/library/papers/29529169PubMed
611807147CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma.N Engl J Med2002https://conductscience.org/library/papers/11807147PubMed
730987939
Abiraterone acetate plus prednisone in patients with newly diagnosed high-risk metastatic castration-sensitive prostate cancer (LATITUDE): final overall survival analysis of a randomised, double-blind, phase 3 trial.
Lancet Oncol2019https://conductscience.org/library/papers/30987939PubMed
82437455Treatment of disseminated germ-cell tumors with cisplatin, bleomycin, and either vinblastine or etoposide.N Engl J Med1987https://conductscience.org/library/papers/2437455PubMed
935179323Darolutamide and Survival in Metastatic, Hormone-Sensitive Prostate Cancer.N Engl J Med2022https://conductscience.org/library/papers/35179323PubMed
1030355464Radiotherapy to the primary tumour for newly diagnosed, metastatic prostate cancer (STAMPEDE): a randomised controlled phase 3 trial.Lancet2018https://conductscience.org/library/papers/30355464PubMed
1136795843Darolutamide Plus Androgen-Deprivation Therapy and Docetaxel in Metastatic Hormone-Sensitive Prostate Cancer by Disease Volume and Risk Subgroups in the Phase III ARASENS Trial.J Clin Oncol2023https://conductscience.org/library/papers/36795843PubMed
1229384722Chemohormonal Therapy in Metastatic Hormone-Sensitive Prostate Cancer: Long-Term Survival Analysis of the Randomized Phase III E3805 CHAARTED Trial.J Clin Oncol2018https://conductscience.org/library/papers/29384722PubMed
1331157964Enzalutamide with Standard First-Line Therapy in Metastatic Prostate Cancer.N Engl J Med2019https://conductscience.org/library/papers/31157964PubMed
1433914595Apalutamide in Patients With Metastatic Castration-Sensitive Prostate Cancer: Final Survival Analysis of the Randomized, Double-Blind, Phase III TITAN Study.J Clin Oncol2021https://conductscience.org/library/papers/33914595PubMed

Download CSV of references

Cited by5

The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 8 citations.

PMIDTitleJournalYearIn PapersSource
42112615The emerging role of prostate-specific membrane antigen-targeted radioligand therapy in metastatic hormone-sensitive prostate cancer.Oncologist2026https://conductscience.org/library/papers/42112615PubMed
42086938Managing patients with recurrent prostate cancer who refuse ADT.Nat Rev Urol2026https://conductscience.org/library/papers/42086938PubMed
40862806Evolving Treatment Paradigms in Metastatic Hormone-Sensitive Prostate Cancer: Expert Narrative Review.Curr Oncol2025https://conductscience.org/library/papers/40862806PubMed
39330003
Outcomes of First Subsequent Taxane Therapy in Patients with Metastatic Castration-Resistant Prostate Cancer Who Previously Received Docetaxel Intensification for Metastatic Castration-Sensitive Prostate Cancer.
Curr Oncol2024https://conductscience.org/library/papers/39330003PubMed
38291265Metastatic Hormone-Sensitive Prostate Cancer in the Era of Doublet and Triplet Therapy.Curr Treat Options Oncol2024https://conductscience.org/library/papers/38291265PubMed

Download CSV of cited by

Data dates

The date of each source this release read.

PubMed
2026-11-06
PubMed
iCite
2026-11-05
iCite
PMC's ID file
2026-11-05
PMC's ID file
NIH RePORTER's grant and paper links
2026-11-01
NIH RePORTER's grant and paper links
Trials
2026-11-12
Gene search
2026-11-11
Pipelines
2026-09-18

None in this release

  • Grants
  • Trials
  • Genes
  • Drugs
  • Data

Sources 11

  • ChEMBL, through Open TargetsCC BY-SA 3.0
  • ClinicalTrials.govNo license stated
  • HGNCCC0
  • iCiteCC BY 4.0
  • NCBI GenePublic domain (US government)
  • NIH RePORTER's grant and paper linksPublic domain
  • Open TargetsCC0 1.0
  • PMC's ID filePublic domain (US government)
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0
Each source's terms
  • ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • ClinicalTrials.govnone stated
  • HGNCCC0: https://www.genenames.org/about/license/
  • iCiteCC BY 4.0
  • NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
  • Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this paper from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/papers/v1/36947730

GET https://conductscience.org/api/papers/v1/36947730/authors